Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722276 | 0.84 | ALDH1A1 (0.46) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL6030691 | 0.79 | CYP3A4 (0.51) | HSPA5AKR1B1TSHRCYP2D6HIF1A | |
| SCHEMBL6059742 | 0.78 | ALDH1A1 (0.44) | TSHRCA12ALDH1A1 | |
| SCHEMBL28671608 | 0.76 | MGLL (0.47) | HSPA5AKR1B1TSHRCYP2D6HIF1A | |
| SCHEMBL11229770 | 0.76 | ALDH1A1 (0.41) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL4128241 | 0.75 | IDO1 (0.53) | HSPA5AKR1B1TSHRCYP2D6HIF1A | |
| SCHEMBL5183966 | 0.75 | MGLL (0.50) | HSPA5AKR1B1TAAR1CA12CA2 | |
| SCHEMBL1696805 | 0.74 | ALDH1A1 (0.64) | TSHRCYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL3019254 | 0.74 | TAAR1 (0.45) | TSHRTAAR1IDO1ALDH1A1 | |
| SCHEMBL6918417 | 0.74 | ALDH1A1 (0.39) | TSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152249-A1 | CURABLE COMPOSITION FOR AN ELECTRICAL MACHINE, AND ASSOCIATED METHOD | General Electric Company (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187928-A1 | CURABLE COMPOSITION FOR AN ELECTRICAL MACHINE, AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-6831094-B2 | For therapy of central nervous system disorders such as anxiety, depression, motor disorders | WYETH | 2004-12-14 | — | — | US | disclosed |
| US-6815456-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-09 | — | — | US | disclosed |
| EP-1392682-A2 | HETEROCYCLYLALKOXY-, -ALKYLTHIO- AND -ALKYLAMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1385842-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-04-24 | — | — | US | disclosed |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2002085892-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085853-A2 | HETEROCYCLYLALKOXY-, -ALKYLTHIO- AND -ALKYLAMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HSPA5 3556/4885AKR1B1 838/4885TSHR 218/4885 |
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HSPA5 3679/4885AKR1B1 805/4885TSHR 177/4885 |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HSPA5 3676/4885AKR1B1 785/4885TSHR 224/4885 |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HSPA5 3713/4885AKR1B1 717/4885TSHR 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.